Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $77

Morgan Stanley maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $73 to $77.

Benzinga · 01/17/2020 13:31

Morgan Stanley maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $73 to $77.